Investigating a schizophrenia drug as a new therapy against dementia

Now, in collaboration with international scientists, the MHH team has investigated the effect of the antipsychotic amisulpride on the receptor. The drug, which is approved for the treatment of schizophrenia, can block the 5-HT7R and thus prevent the pathological accumulation of the tau protein. The effect of amisulpride has been successfully tested in various cellular models as well as in animal models of dementia. The results have now been published in the journal Alzheimer’s & Dementia .


I asked Bing’s A.I. if Abilify blocks 5-HT7R too.

Yes, aripiprazole (Abilify) has high affinity at 5-HT7R receptors². This receptor is involved in the regulation of mood and cognition¹.

Source: Conversation with Bing, 25/05/2023
(1) Update on the Mechanism of Action of Aripiprazole: Translational …
(2) Current Limitations and Candidate Potential of 5-HT7 Receptor …
(3) Serotonin drives the acquisition of a profibrotic and anti … - Nature. Serotonin drives the acquisition of a profibrotic and anti-inflammatory gene profile through the 5-HT7R-PKA signaling axis | Scientific Reports.